Skip to main content
Back to News
Insitro has acquired CombinAble.AI, marking the first exit for an Israeli AI pharma startup. Built b...
Acquisition
1 min read

Insitro has acquired CombinAble.AI, marking the first exit for an Israeli AI pharma startup. Built b...

The AMW Read

Updates the player map for Vertical AI-Bio via the acquisition of CombinAble.AI by Insitro, illustrating high-velocity venture studio exits in the segment.
NoveltySignificance
Healthcare & Bio · Player Map
CombinAble.AI
CombinAble.AI

AI in Biotech / Drug Discovery

View Company Profile

Insitro has acquired CombinAble.AI, marking the first exit for an Israeli AI pharma startup. Built by AION Labs, the venture reached acquisition in just 2 years with a rapid 4-month deal process. The integration of physics-informed AI powers Insitro’s new TherML platform, creating a unified engine for small molecules and biologics. This shift to generative design validates the venture studio model as a high-velocity catalyst for biotech. 🚀💊

#AI #DrugDiscovery #Biotech #Insitro #Acquisition #IsraelTech

How This Connects

Based on Healthcare & Bio · Player Map

  1. 4d agoIsomorphic Labs raises $5 billion Series C for AI drug discoveryIsomorphic Labs
  2. 0mo agoPathos AI raises $237M to scale Foundry and advance four oncology assetsPathos
  3. 1mo agoWarp Sciences, founded by former OpenAI science lead Kevin Weil, raises $215M to automate drug-chemistry labsWarp Sciences
  4. 10mo agoInsitro has acquired CombinAble.AI, marking the first exit for an Israeli AI pharma startup. Built b... · THIS ARTICLE

More news from CombinAble.AI

Stay updated with the latest news and announcements from CombinAble.AI.

View all CombinAble.AI news

Discover AI Startups

Explore 5,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard